|
EP2828290B1
(en)
*
|
2012-03-23 |
2018-08-15 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
EP3327037B1
(en)
|
2012-08-21 |
2019-10-09 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2016133829A1
(en)
*
|
2015-02-17 |
2016-08-25 |
Full Spectrum Genetics, Inc. |
Novel sd1 binding compounds and uses thereof
|
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
WO2017032293A1
(zh)
*
|
2015-08-21 |
2017-03-02 |
科济生物医药（上海）有限公司 |
抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
|
|
CA3289997A1
(en)
|
2015-09-20 |
2026-03-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use
|
|
EP4643874A3
(en)
|
2015-12-22 |
2026-02-11 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
WO2017201493A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
EP3494135A1
(en)
*
|
2016-08-02 |
2019-06-12 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US20190218294A1
(en)
|
2016-09-09 |
2019-07-18 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
WO2018067993A1
(en)
*
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
AU2017363300A1
(en)
|
2016-11-23 |
2019-06-20 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
WO2018098356A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
AU2017382883B2
(en)
|
2016-12-21 |
2024-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
CA3057838A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
|
EP3621994A4
(en)
*
|
2017-05-12 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
MESOTHELIN BINDING PROTEINS
|
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
WO2018213612A1
(en)
*
|
2017-05-18 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides and proteins
|
|
WO2018213064A1
(en)
|
2017-05-19 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
|
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
|
WO2019043026A1
(en)
*
|
2017-08-30 |
2019-03-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTI-MESOTHELIC RADIOMARQUATED SINGLE DOMAIN ANTIBODIES SUITABLE FOR IMAGING AND TREATING CANCERS
|
|
MX2020003915A
(es)
|
2017-10-13 |
2020-10-08 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso.
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
KR101966362B1
(ko)
*
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
|
CN111683962B
(zh)
|
2017-11-10 |
2025-05-16 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向肿瘤抗原的嵌合抗原受体
|
|
WO2019118760A1
(en)
*
|
2017-12-13 |
2019-06-20 |
Inovio Pharmaceuticals, Inc. |
Cancer vaccines targeting mesothelin and uses thereof
|
|
CN108129566B
(zh)
*
|
2017-12-31 |
2021-05-11 |
中国科学院武汉病毒研究所 |
靶向间皮素的c-型单域抗体及其制备方法与应用
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
US12312416B2
(en)
|
2018-02-06 |
2025-05-27 |
Seattle Children's Hospital |
Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
|
|
AU2019225174B2
(en)
|
2018-02-23 |
2025-11-20 |
Endocyte, Inc. |
Sequencing method for CAR T cell therapy
|
|
JP7496324B2
(ja)
|
2018-03-16 |
2024-06-06 |
サイファー メディシン コーポレイション |
抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
EP3806889A4
(en)
*
|
2018-06-18 |
2022-07-13 |
Anwita Biosciences, Inc. |
CYTOKI FUSION PROTEINS AND USES THEREOF
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
PT3820569T
(pt)
|
2018-07-12 |
2025-01-14 |
Invox Pharma Ltd |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
ES3044118T3
(en)
|
2018-07-12 |
2025-11-26 |
Invox Pharma Ltd |
Antibody molecules that bind cd137 and ox40
|
|
US11939377B2
(en)
|
2018-07-12 |
2024-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
EP3833684A1
(en)
|
2018-08-08 |
2021-06-16 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
CA3111087A1
(en)
|
2018-08-29 |
2020-03-05 |
Nanjing Legend Biotech Co., Ltd. |
Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
|
|
KR20210069048A
(ko)
|
2018-08-30 |
2021-06-10 |
티씨알2 테라퓨틱스 인크. |
융합 단백질을 이용하는 tcr 재프로그래밍을 위한 조성물 및 방법
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
CN109406765B
(zh)
*
|
2018-10-23 |
2022-02-01 |
大连博格林生物科技有限公司 |
细胞增殖与毒性检测试剂盒
|
|
CA3125484A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
US12122843B2
(en)
|
2019-01-22 |
2024-10-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
JP7698581B2
(ja)
|
2019-03-29 |
2025-06-25 |
グリーン・クロス・コーポレイション |
抗メソテリン抗体、抗ｃｄ３抗体又は抗ｅｇｆｒ抗体を含む融合タンパク質、それを含む二重特異性又は三重特異性抗体、及びその使用
|
|
AU2020275002A1
(en)
|
2019-05-14 |
2021-12-23 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
GB2603294A
(en)
|
2019-06-27 |
2022-08-03 |
Scipher Medicine Corp |
Developing classifiers for stratifying patients
|
|
CA3156761A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
WO2021090062A1
(en)
*
|
2019-11-07 |
2021-05-14 |
Eisai R&D Management Co., Ltd. |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use
|
|
CN115210252A
(zh)
|
2020-02-04 |
2022-10-18 |
西雅图儿童医院（Dba西雅图儿童研究所） |
抗二硝基苯酚的嵌合抗原受体
|
|
CN115768463A
(zh)
|
2020-02-21 |
2023-03-07 |
哈普恩治疗公司 |
Flt3结合蛋白及使用方法
|
|
EP4175650A1
(en)
*
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
KR20230126714A
(ko)
*
|
2020-12-18 |
2023-08-30 |
바이오아르디스 엘엘씨 |
메소텔린 결합 분자 및 이의 사용
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
EP4333983A4
(en)
*
|
2021-05-07 |
2025-07-30 |
Kiromic Biopharma Inc |
MESOTHELIN ISOFORM-BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THEM AND USES THEREOF
|
|
US20240270851A1
(en)
|
2021-06-09 |
2024-08-15 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
WO2023051414A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
北恒医疗有限公司 |
靶向间皮素的抗体及其用途
|
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
|
MX2024004550A
(es)
*
|
2021-10-14 |
2024-04-29 |
Teneobio Inc |
Proteinas de union a la mesotelina y usos de las mismas.
|
|
JP2024537991A
(ja)
|
2021-10-14 |
2024-10-18 |
アーセナル バイオサイエンシズ インコーポレイテッド |
共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
|
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
WO2023114980A1
(en)
|
2021-12-17 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
|
|
CN116410332B
(zh)
*
|
2021-12-29 |
2025-04-15 |
上海细胞治疗集团股份有限公司 |
抗间皮素纳米抗体嵌合抗原受体及其应用
|
|
JP2025505933A
(ja)
*
|
2022-01-06 |
2025-03-05 |
オリセル セラピューティクス カンパニー リミテッド |
Ｍｓｌｎを標的とする抗原結合タンパク質及びその使用
|
|
JP2025529210A
(ja)
|
2022-09-01 |
2025-09-04 |
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド |
アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
|
|
US20260070960A1
(en)
|
2022-09-01 |
2026-03-12 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN116003638B
(zh)
*
|
2023-01-20 |
2023-09-05 |
北京基因启明生物科技有限公司 |
一种有效杀伤胆管型肝癌的CAR-iNKT细胞技术
|
|
WO2024165567A1
(en)
*
|
2023-02-06 |
2024-08-15 |
Universite D'aix-Marseille |
Anti-mesothelin nanobodies, constructs and conjugates
|
|
AU2024260837A1
(en)
|
2023-04-25 |
2025-10-16 |
Arsenal Biosciences, Inc. |
Novel receptors for transcription regulation
|
|
WO2024238346A1
(en)
|
2023-05-12 |
2024-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
|
|
CN116751300A
(zh)
*
|
2023-06-15 |
2023-09-15 |
上海斯丹赛生物技术有限公司 |
抗间皮素重链单域抗体及其在癌症治疗中的应用
|
|
AU2024295016A1
(en)
|
2023-07-20 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025063790A1
(ko)
*
|
2023-09-20 |
2025-03-27 |
주식회사 유씨아이테라퓨틱스 |
항-메소텔린 항체 및 이의 용도
|
|
WO2025143287A1
(ko)
*
|
2023-12-27 |
2025-07-03 |
서울대학교산학협력단 |
메소텔린에 특이적인 항체 및 이의 용도
|
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|